Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galicaftor/Navocaftor/ABBV-119 or ABBV-576 Combination Therapies in Cystic Fibrosis
NCT04853368Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of ABBV-119 and ABBV-576 in cystic fibrosis (CF) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Absolute Change From Baseline Through Day 29 in Percent Predicted Forced Expiratory Volume in 1 Second and Absolute Change From Baseline Through Day 29 in Sweat Chloride. Started Sep 2021; status: terminated.
02
Drugs
ABBV-119ABBV-576
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04853368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853368.